ScholarIQanswers from OpenAlex & ORCID
Jean‐Pierre Delord
ResearcherPublications, citations & collaboration network
Jean‐Pierre Delord is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jean‐Pierre Delord have?
ScholarIQindexed works
Jean‐Pierre Delord has 500 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jean‐Pierre Delord have?
ScholarIQcitation count
Jean‐Pierre Delord has 23,488 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jean‐Pierre Delord?
ScholarIQh-index
Jean‐Pierre Delord has an h-index of 65 in OpenAlex.
What is the i10-index of Jean‐Pierre Delord?
ScholarIQi10-index
Jean‐Pierre Delord has an i10-index of 203 in OpenAlex.
What is the ORCID of Jean‐Pierre Delord?
ScholarIQorcid
The ORCID for Jean‐Pierre Delord is on the source record.
What is the OpenAlex record for Jean‐Pierre Delord?
ScholarIQopenalex
The OpenAlex for Jean‐Pierre Delord is on the source record.
What are the most-cited papers on Jean‐Pierre Delord?
ScholarIQmost cited works
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung‐Ju Ahn, Ainara Soria, Jean‐Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan D. Cheng, Ramona F. Swaby, Kevin J. Harrington, Mirelis Acosta-Rivera, Douglas R. Adkins, Morteza Aghmesheh, Myung‐Ju Ahn, Mario Airoldi, Eduardas Aleknavičius, Yousuf Al-Farhat, Alain P. Algazi, Salah Almokadem, Anna Alyasova, Jessica R. Bauman, Marco Benasso, Alfonso Berrocal, Victoria Bray, Barbara Burtness, Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García, Fabrice André, Jean‐Pierre Delord, Manuel Hidalgo, Jan H.M. Schellens, Philippe A. Cassier, D. Ross Camidge, Martin Schüler, Ulka N. Vaishampayan, Howard A. Burris, Guangming Tian, Mario Campone, Zev A. Wainberg, Wan‐Teck Lim, Patricia LoRusso, Geoffrey I. Shapiro, Katie Parker, Xueying Chen, Somesh Choudhury, François Ringeisen, Diana Graus-Porta, Dale Porter, Randi Isaacs, Reinhard Buettner, Jürgen Wolf
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin, Jean‐Charles Soria, Anastasios Stathis, Jean‐Pierre Delord, Solange Peters, Ahmad Awada, Philippe Aftimos, Mohamed Békradda, Keyvan Rezaï, Zhen Zeng, Azher Hussain, Susan Perez, Lillian L. Siu, Christophe Massard